FFO
TELO icon

Fortitude Family Office’s Telomir Pharmaceuticals TELO Stock Holding History

Fortitude Family Office’s Portfolio TELO Stock Details TELO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,347
Closed -$1.79K – 2098
2025
Q4 		$1.79K Buy
+1,347
New +$1.94K ﹤0.01% 1223
2025
Q3 		– Sell
-667
Closed -$834 – 2158
2025
Q2 		$834 Buy
+667
New +$1.54K ﹤0.01% 1595

Other funds holding TELO

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
SEM
Suncoast Equity Management Tampa, Florida $833M AUM 11.9% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
WIA
World Investment Advisors Santa Barbara, California $6.2B AUM 19.68% 1-Year Est. Return

Fortitude Family Office's TELO Position: Q1 2026 in Review

Fortitude Family Office sold out of Telomir Pharmaceuticals (TELO) in Q1 2026, closing a stake of 1,347 shares — an estimated $1.79K sold.

Fortitude Family Office first reported a position in TELO in Q2 2025 and held it in 2 quarters. The position peaked at $1.79K in Q4 2025. 27 funds tracked by Wall St. Rank hold TELO as of Q1 2026.

  • Fortitude Family Office reported no remaining Telomir Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Fortitude Family Office sold 1,347 Telomir Pharmaceuticals shares in Q1 2026, an estimated $1.79K.
  • Fortitude Family Office first reported a position in Telomir Pharmaceuticals in Q2 2025 and held it in 2 quarters.
  • Fortitude Family Office's Telomir Pharmaceuticals position peaked at $1.79K in Q4 2025.
  • 27 funds tracked by Wall St. Rank held Telomir Pharmaceuticals as of Q1 2026.

Based on Fortitude Family Office's 13F filing for Q1 2026, filed 16 Apr 2026.